These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 155195)

  • 1. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
    Tolosa ES
    Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
    [No Abstract]   [Full Text] [Related]  

  • 2. The endocrinology of extrapyramidal system disorders.
    Kirkpatrick B; Tamminga CA
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):159-72. PubMed ID: 2967753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine therapy for Parkinson's disease and other movement disorders.
    Pfeiffer C; Wagner ML
    Am J Hosp Pharm; 1994 Dec; 51(24):3047-53. PubMed ID: 7856623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choline chloride in the treatment of Huntington's disease and tardive dyskinesia: a preliminary report.
    Davis KL; Berger PA; Hollister LE; Simonton SC
    Psychopharmacol Bull; 1977 Jul; 13(3):37-8. PubMed ID: 142261
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug holiday in Huntington's disease.
    Schmidt EZ; Hofmann P; Kapfhammer HP; Bonelli RM
    Ann Pharmacother; 2005 Apr; 39(4):773. PubMed ID: 15741414
    [No Abstract]   [Full Text] [Related]  

  • 7. The endocrinology of extrapyramidal system disorders.
    Kirkpatrick B; Tamminga CA
    Neurol Clin; 1988 Feb; 6(1):159-72. PubMed ID: 2967909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABA and movement disorders.
    Marsden CD; Sheehy MP
    Adv Biochem Psychopharmacol; 1981; 30():225-34. PubMed ID: 6460427
    [No Abstract]   [Full Text] [Related]  

  • 9. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oculomotor abnormalities in diseases of the basal ganglia.
    Kennard C; Lueck CJ
    Rev Neurol (Paris); 1989; 145(8-9):587-95. PubMed ID: 2530611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
    Fenney A; Jog MS; Duval C
    Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
    Walters AS; McHale D; Sage JI; Hening WA; Bergen M
    Clin Neuropharmacol; 1990 Jun; 13(3):236-40. PubMed ID: 2141544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 15. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
    Stahl SM; Davis KL; Berger PA
    J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in Parkinson's disease and Huntington's chorea.
    Barbeau A
    Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
    [No Abstract]   [Full Text] [Related]  

  • 18. The emerging role of clozapine in the treatment of movement disorders.
    Factor SA; Friedman JH
    Mov Disord; 1997 Jul; 12(4):483-96. PubMed ID: 9251065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
    Destee A
    LARC Med; 1984 Feb; 4(2):107-11. PubMed ID: 6232436
    [No Abstract]   [Full Text] [Related]  

  • 20. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.